Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for TSC-associated renal angiomyolipoma
ChiCTR-OPC-14005488Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in kidney angiomyolipoma (AML), sponsored by Peking Union Medical College Hospital. Primary endpoints: Maximum tumor diameter or volume, TSC1 and TSC2 mutations and 1 more. Started Nov 2014; status: recruiting.
02
Drugs
everolimus
03
Conditions
kidney angiomyolipoma (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-14005488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-14005488.